Upregulation of drug transporter expression by osteopontin in prostate cancer cellss

I. Shan Hsieh, Wei Hsun Huang, Houng Chi Liou, Woei Jer Chuang, Rong Sen Yang, Wen Mei Fu

研究成果: Article同行評審

30 引文 斯高帕斯(Scopus)

摘要

Multidrug resistance is a major cause of chemotherapy failure. Recent studies indicate that drug resistance can be rapidly induced by some soluble factors, such as cytokines, chemokines, growth factors, and cell adhesion factors in the tumor microenvironment. Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-aspartic acid (RGD) domain for binding to integrin. Here we found OPN expression to be upregulated by hypoxic condition in PC-3 prostate tumor cells. OPN increased the mRNA and protein expression of pglycoprotein (P-gp), a subfamily of ATP-binding cassette transporter in a concentration- and time-dependent manner. The increase in P-gp transporter by OPN was mediated by binding to avb3 integrin. Daunomycin (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and OPN increased the drug pumping-out activity. OPN inhibited DUN-induced cell death, which was antagonized by avb3 monoclonal antibody. Long-term treatment with DUN further enhanced the expression of OPN. Knockdown of endogenous OPN potentiated the DUN-induced apoptosis of PC-3 cells. Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin- D, and rapamycin, which are also P-gp substrates. The animal studies also showed that OPN knockdown enhanced the cytotoxic action of DUN. These results indicate that OPN is a potential therapeutic target for cancer therapy to reduce drug resistance in sensitive tumors.

原文English
頁(從 - 到)968-977
頁數10
期刊Molecular Pharmacology
83
發行號5
DOIs
出版狀態Published - 2013 五月

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

指紋 深入研究「Upregulation of drug transporter expression by osteopontin in prostate cancer cellss」主題。共同形成了獨特的指紋。

引用此